Fairmont Banff Springs Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2020
Here are the related meetings in 2021:
Plant Genome Engineering: From Lab to Field (EK25)
Precision Engineering of the Genome, Epigenome and Transcriptome (EK24)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Engineering the Genome (Q2)
Organizer(s) Vic Myer and Erik Sontheimer
February 8—12, 2020
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 29, 2019
Abstract Deadline: Nov 6, 2019
Scholarship Deadline: Oct 29, 2019
Discounted Registration Deadline: Dec 10, 2019
Sponsored by Editas Medicine and Novo Nordisk A/S
Joint Meeting:
Emerging Cellular Therapies: Cancer and Beyond (Q1)
Summary of Meeting:
Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.
View Scholarships/Awards
Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Saturday, February 8 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 12 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, February 13 in order to fully experience the meeting.
SATURDAY, FEBRUARY 8
SUNDAY, FEBRUARY 9
MONDAY, FEBRUARY 10
TUESDAY, FEBRUARY 11
WEDNESDAY, FEBRUARY 12
THURSDAY, FEBRUARY 13
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Saturday, February 8 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, February 12 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, February 13 in order to fully experience the meeting.
SATURDAY, FEBRUARY 8
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
Welcome and Keynote Session (Joint)
*
Vic E. Myer,
Atlas Ventures, USA
*
Crystal L. Mackall,
Stanford University, USA
Jennifer A. Doudna,
HHMI/University of California, Berkeley, USA
Genome Editing with CRISPR-Cas Systems: Challenges and Opportunities in a New Era of Biology
Genome Editing with CRISPR-Cas Systems: Challenges and Opportunities in a New Era of Biology
Coffee Break
09:50—12:00
Biochemistry, Biophysics and New Enzymes
Kira S. Makarova,
National Center for Biotechnology Information, USA
In silico Discovery of New Defense Systems
In silico Discovery of New Defense Systems
*
Erik Sontheimer,
University of Massachusetts Medical School, USA
RNA-Guided RNA/DNA Cleavage by CRISPR-Cas Systems
RNA-Guided RNA/DNA Cleavage by CRISPR-Cas Systems
Ilya J. Finkelstein,
University of Texas at Austin, USA
Massively-Parallel Profiling of Natural and Engineered High-Fidelity CRISPR Nucleases
Massively-Parallel Profiling of Natural and Engineered High-Fidelity CRISPR Nucleases
Ervin Welker,
Research Center of Natural Sciences, Hungary
Short Talk: Ranking between Increased Fidelity SpCas9 Nucleases and Target Sites
Short Talk: Ranking between Increased Fidelity SpCas9 Nucleases and Target Sites
Garrett R. Rettig,
Integrated DNA Technologies, USA
Short Talk: Engineered A.s. and L.b. Cas12a (Cpf1) Variants with Enhanced Activity
Short Talk: Engineered A.s. and L.b. Cas12a (Cpf1) Variants with Enhanced Activity
09:50—12:00
Genetically Engineered T Cell Therapies for Cancer: Results from the Clinic
*
Chiara Bonini,
Ospedale San Raffaele, Italy
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
CAR T Cells for Solid Tumors
CAR T Cells for Solid Tumors
Yvonne Y. Chen,
University of California, Los Angeles, USA
Synthetic Biology to Engineer More Potent CAR T Cells
Synthetic Biology to Engineer More Potent CAR T Cells
Kristen Hege,
Celgene, USA
Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma
Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma
Brooke Prinzing,
St. Jude Children's Research Hospital, USA
Short Talk: Chimeric Antigen Receptors with a MyD88 and CD40 Costimulatory Endodomain Endow T Cells with Superior Antitumor Activity
Short Talk: Chimeric Antigen Receptors with a MyD88 and CD40 Costimulatory Endodomain Endow T Cells with Superior Antitumor Activity
Evan William Weber,
Stanford University, USA
Short Talk: The Src Kinase Inhibitor, Dasatinib, Enhances CAR-T Cell Potency by Mitigating T Cell Exhaustion
Short Talk: The Src Kinase Inhibitor, Dasatinib, Enhances CAR-T Cell Potency by Mitigating T Cell Exhaustion
14:30—16:30
Panel: Ethics of Genome Editing
*
Tim Hunt,
Editas Medicine, USA
Ethics of Genome Editing: Framing the Discussion
Ethics of Genome Editing: Framing the Discussion
Fyodor D. Urnov,
University of California, Berkeley, USA
Kathy K. Niakan,
Francis Crick Institute, UK
Krishanu Saha,
University of Wisconsin-Madison, USA
14:30—16:30
Workshop 1: Platforms for Immune Cell Engineering
*
Manfred Lehner,
Children's Cancer Research Institute, Austria
Carla Alicia Jaeger-Ruckstuhl,
Fred Hutchinson Cancer Research Center, USA
The Role of CD27 Co-Stimulation during CAR-T Cell Generation and Immunotherapy
The Role of CD27 Co-Stimulation during CAR-T Cell Generation and Immunotherapy
Benjamin Salzer,
Children's Cancer Research Institute, Austria
AvidCARs – A Novel Platform for Inducible and Combinatorial CAR Control
AvidCARs – A Novel Platform for Inducible and Combinatorial CAR Control
Alec Wilkens,
Fred Hutchinson Cancer Research Center, USA
NOTCH1 Agonism Alters Phenotype and Function of Gene Engineered CD4+ T Cells
NOTCH1 Agonism Alters Phenotype and Function of Gene Engineered CD4+ T Cells
Michela Consonni,
Fondazione Centro San Raffaele, Italy
Donor-Unrestricted Adoptive T Cell Therapy of Acute Leukemia by CD1c-Restricted TCR Transfer
Donor-Unrestricted Adoptive T Cell Therapy of Acute Leukemia by CD1c-Restricted TCR Transfer
Amy N. Courtney,
Baylor College of Medicine, USA
NKT Cells Suppress Metastatic Spread of Neuroblastoma by Controlling Tumor-Associated Macrophages
NKT Cells Suppress Metastatic Spread of Neuroblastoma by Controlling Tumor-Associated Macrophages
Hyun Cheol Jung,
Korea Advanced Institute of Science and Technology, South Korea
Elimination of Amyloid-beta Plaques by Chimeric Phagocytic Receptors
Elimination of Amyloid-beta Plaques by Chimeric Phagocytic Receptors
Charlotte U. Brey,
Children's Cancer Research Institute, Austria
A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug
A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug
17:00—19:00
In vivo Genome Editing
*
Fyodor D. Urnov,
University of California, Berkeley, USA
Edward J. Rebar,
Sangamo Therapeutics, Inc., USA
Liver Editing in vivo for Therapeutic Gene Expression
Liver Editing in vivo for Therapeutic Gene Expression
Jessica Seitzer,
Intellia Therapeutics Inc., USA
Short Talk: In vivo Delivery of CRISPR/Cas9 to the Liver using Lipid Nanoparticles Enables Gene Knockout across Multiple Targets in Rodent and Non-Human Primates
Short Talk: In vivo Delivery of CRISPR/Cas9 to the Liver using Lipid Nanoparticles Enables Gene Knockout across Multiple Targets in Rodent and Non-Human Primates
David V. Schaffer,
University of California, Berkeley, USA
Engineering and Evolving New Viruses for Gene Therapy and Genome Editing
Engineering and Evolving New Viruses for Gene Therapy and Genome Editing
Jessie R. Davis,
Harvard University, USA
Short Talk: Cytosine and Adenine Base Editing of Brain, Retina, Heart, Muscle, and Liver Mediated by AAV
Short Talk: Cytosine and Adenine Base Editing of Brain, Retina, Heart, Muscle, and Liver Mediated by AAV
17:00—19:00
Engineered Hematopoietic Stem Cells for Treatment of Genetic Diseases
*
Gloria Delfanti,
San Raffaele Scientific Institute, Italy
Marina Cavazzana,
Paris Descartes University, France
Gene Therapy for Immunodeficiencies
Gene Therapy for Immunodeficiencies
Alessandra Biffi,
Dana-Farber Cancer Institute, Boston Children's Hospital, USA
Engineered HSCs for Correction of CNS Disorders
Engineered HSCs for Correction of CNS Disorders
Sebastian Ricardo Palacios,
Massachusetts Institute of Technology, USA
Short Talk: Engineered RNAi-based Logic Circuits in Human Induced Pluripotent Stem Cells and their Differentiated Derivatives
Short Talk: Engineered RNAi-based Logic Circuits in Human Induced Pluripotent Stem Cells and their Differentiated Derivatives
Esmond Lee,
Stanford, USA
Short Talk: CRISPR- Based Gene Editing Enables FOXP3 Gene Repair in IPEX Patient Cells and HSPCs
Short Talk: CRISPR- Based Gene Editing Enables FOXP3 Gene Repair in IPEX Patient Cells and HSPCs
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Genome Editing as a Biology Discovery Tool
*
David R. Liu,
Broad Institute, HHMI, and Harvard University, USA
Kathy K. Niakan,
Francis Crick Institute, UK
Towards an Understanding of Human Development Using Gene Ablation
Towards an Understanding of Human Development Using Gene Ablation
Hannah N. De Jong,
Stanford University, USA
Short Talk: Deep Mutational Scanning to Identify Cardiac Disease Gene Variants
Short Talk: Deep Mutational Scanning to Identify Cardiac Disease Gene Variants
Philipp Junker,
Max Delbrück Center for Molecular Medicine, Germany
Massively Parallel Lineage Tracing Using CRISPR/Cas9
Massively Parallel Lineage Tracing Using CRISPR/Cas9
Coffee Break
Alan Huang,
Tango Therapeutics, USA
Novel Therapeutic Opportunities Identified by Synthetic Lethal Screening
Novel Therapeutic Opportunities Identified by Synthetic Lethal Screening
Andrew Ravanelli,
MilliporeSigma, USA
Short Talk: Direct Capture of CRISPR Guides Enables Scalable, Multiplexed, and Multi-Omic Genetic Screens
Short Talk: Direct Capture of CRISPR Guides Enables Scalable, Multiplexed, and Multi-Omic Genetic Screens
Birgit C. Schultes,
IntelliaTherapeutics Inc., USA
Developing Next-Generation Engineered TCR-T Cells with CRISPR
Developing Next-Generation Engineered TCR-T Cells with CRISPR
Barbara Mair,
University of Toronto, Canada
Short Talk: High-Throughput Genome-Wide Phenotypic Screening via Immunomagnetic Cell Sorting Identifies QPCTL as Modulator of CD47
Short Talk: High-Throughput Genome-Wide Phenotypic Screening via Immunomagnetic Cell Sorting Identifies QPCTL as Modulator of CD47
08:00—11:15
Next Generation Immune Cell Engineering
*
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
Crystal L. Mackall,
Stanford University, USA
Engineering Enhanced Potency T Cells
Engineering Enhanced Potency T Cells
Chiara Bonini,
Ospedale San Raffaele, Italy
Multiple Genome Editing of Early Differentiated T Cells for Cancer Immunotherapy
Multiple Genome Editing of Early Differentiated T Cells for Cancer Immunotherapy
Coffee Break
Christopher A. Klebanoff,
Memorial Sloan Kettering Cancer Center, USA
Targeting Solid Malignancies with "Public" Neoantigen TCRs
Targeting Solid Malignancies with "Public" Neoantigen TCRs
Aude G. Chapuis,
Fred Hutchinson Cancer Research Center, USA
Optimizing T Cell Receptor Gene Therapy Against Solid and Liquid Tumors
Optimizing T Cell Receptor Gene Therapy Against Solid and Liquid Tumors
Christie Ciarlo,
Altius Institute for Biomedical Sciences, USA
Short Talk: Engineering Superior T Cell Therapies without Genetic Modification
Short Talk: Engineering Superior T Cell Therapies without Genetic Modification
Giedre Krenciute,
St Jude Children's Research Hospital, USA
Short Talk: DNMT3a-Mediated Epigenetic Programming Limits CAR T Cell Survival and Effector Function
Short Talk: DNMT3a-Mediated Epigenetic Programming Limits CAR T Cell Survival and Effector Function
Debattama Sen,
Massachusetts General Hospital, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control
15:00—16:30
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
*
Yan Zhang,
University of Michigan, USA
Joseph Bondy-Denomy,
University of California, San Francisco, USA
Inhibition of CRISPR-Cas9 and Cas12 with Bacteriophage Proteins
Inhibition of CRISPR-Cas9 and Cas12 with Bacteriophage Proteins
Jan Mathony,
Heidelberg University, Germany
Computational Design of Anti-CRISPR Proteins with Improved Inhibition Potency
Computational Design of Anti-CRISPR Proteins with Improved Inhibition Potency
Jooyoung Lee,
University of Massachusetts Medical School, USA
Tissue-Restricted Genome Editing in vivo Specified by MicroRNA-Repressible Anti-CRISPR Proteins
Tissue-Restricted Genome Editing in vivo Specified by MicroRNA-Repressible Anti-CRISPR Proteins
Dominik Niopek,
Heidelberg University Hospital, Germany
Switchable Anti-CRISPR Proteins for Precision Control of CRISPR-Cas9 and -12
Switchable Anti-CRISPR Proteins for Precision Control of CRISPR-Cas9 and -12
Jennifer R. Hamilton,
University of California, Berkeley, USA
Delivery of Anti-CRISPR Proteins by Engineered Virus-Like Particles Therapeutically Protect Cells from CRISPR-Cas9 Gene Editing
Delivery of Anti-CRISPR Proteins by Engineered Virus-Like Particles Therapeutically Protect Cells from CRISPR-Cas9 Gene Editing
15:30—16:30
Workshop 2: HSC and iPSC Engineering and Therapy
*
Katy Rezvani,
University of Texas MD Anderson Cancer Center, USA
Linda T. Vo,
University of California, San Francisco, USA
A Stem Cell Platform for Engineering Distinct T Cell Populations de novo for Immunotherapy
A Stem Cell Platform for Engineering Distinct T Cell Populations de novo for Immunotherapy
Brian Koss,
University of Arkansas for Medical Sciences, USA
Epigenetic Control of Tumor-Infiltrating Lymphocyte Metabolic-Exhaustion
Epigenetic Control of Tumor-Infiltrating Lymphocyte Metabolic-Exhaustion
Bernhard Lehnertz,
University of Montreal, Canada
Engineering of a Genetically Encoded Human Hematopoietic Stem Cell Reporter
Engineering of a Genetically Encoded Human Hematopoietic Stem Cell Reporter
Jose A. Vargas Asencio,
Massachusetts Institute of Technology, USA
Single Cell Sequencing of Developing Liver-Like Organoids Reveals Expression Programs Associated to Germ Line Trajectories Defined by Synthetic Circuits
Single Cell Sequencing of Developing Liver-Like Organoids Reveals Expression Programs Associated to Germ Line Trajectories Defined by Synthetic Circuits
17:00—19:00
Translational Science of Genome Editing: Assessing Specificity, Immunogenicity and Safety
*
Samantha Maragh,
National institute of Standards and Technology, USA
Julian Grünewald,
Massachusetts General Hospital, USA
Advances in Identifying and Modulating the Specificities of Gene Editing Technologies
Advances in Identifying and Modulating the Specificities of Gene Editing Technologies
Richard A. Morgan,
Editas Medicine, USA
Application of Cpf1-Based Genome Editing for ex vivo Cell Therapy
Application of Cpf1-Based Genome Editing for ex vivo Cell Therapy
Krishanu Saha,
University of Wisconsin-Madison, USA
Short Talk: Patient-Derived, Induced Pluripotent Stem Cells as Translational Tools to Assess Specificity, Immunogenicity, and Safety of Somatic Cell Genome Editors
Short Talk: Patient-Derived, Induced Pluripotent Stem Cells as Translational Tools to Assess Specificity, Immunogenicity, and Safety of Somatic Cell Genome Editors
Bruce R. Conklin,
University of California, San Francisco, USA
Short Talk: Modeling Therapeutic Editing in Patient-Derived iPSC Tissues
Short Talk: Modeling Therapeutic Editing in Patient-Derived iPSC Tissues
Zuben E. Sauna,
Food and Drug Administration, USA
Understanding and Navigating the Immune Responses to CRISPR-Associated Nuclease Cas9
Understanding and Navigating the Immune Responses to CRISPR-Associated Nuclease Cas9
17:00—19:00
Cell Therapy for Infection and Autoimmune Diseases
*
Marina Cavazzana,
Paris Descartes University, France
Qizhi Tang,
University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Organ Transplantation
Manipulating Tregs to Control Tolerance in Autoimmunity and Organ Transplantation
Bruce R. Blazar,
University of Minnesota, USA
Treg Therapies in the Setting of Allogeneic HSCT
Treg Therapies in the Setting of Allogeneic HSCT
Hans-Peter Kiem,
Fred Hutchinson Cancer Research Center, USA
Engineering Resistance to HIV Infection
Engineering Resistance to HIV Infection
Megan K. Levings,
University of British Columbia, Canada
CAR-Treg-Based Therapeutics
CAR-Treg-Based Therapeutics
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
CRISPR-Based Editing of Non-Immune Cells (Joint)
*
Jennifer Gori,
Obsidian Therapeutics, USA
Scot A. Wolfe,
University of Massachusetts Medical School, USA
Precise Therapeutic Gene Correction by a Simple Nuclease-Induced Double-Strand Break
Precise Therapeutic Gene Correction by a Simple Nuclease-Induced Double-Strand Break
Coffee Break
Matthew Porteus,
Stanford University School of Medicine, USA
CRISPR Editing of Human HSCs
CRISPR Editing of Human HSCs
Shengdar Q. Tsai,
St. Jude Children's Research Hospital, USA
Short Talk: Highly Efficient Genome Editing of Human Hematopoietic Stem Cells and Fetal Hemoglobin Induction for Sickle Cell Disease Therapy
Short Talk: Highly Efficient Genome Editing of Human Hematopoietic Stem Cells and Fetal Hemoglobin Induction for Sickle Cell Disease Therapy
Alex Marson,
University of California, San Francisco, USA
Reprogramming Human Immune Cell Circuitry
Reprogramming Human Immune Cell Circuitry
Connor A. Tsuchida,
University of California, Berkeley; University of California, San Francisco, USA
Short Talk: Engineering HIV-1 Virus-Like Particles for CRISPR-Cas9 Genome Engineering in Primary Human T Cells
Short Talk: Engineering HIV-1 Virus-Like Particles for CRISPR-Cas9 Genome Engineering in Primary Human T Cells
14:30—16:30
Career Roundtable
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Samuel Haile,
Kite Pharma, USA
Irene Jarchum,
Nature, USA
Yvonne Y. Chen,
University of California, Los Angeles, USA
Kole T. Roybal,
University of California, San Francisco, USA
Eric J. Perkins,
Addgene, USA
17:00—19:00
'Off the Shelf' Allogeneic Cell Therapies (Joint)
*
Crystal L. Mackall,
Stanford University, USA
*
Richard A. Morgan,
Editas Medicine, USA
Daniel Shoemaker,
Fate Therapeutics, USA
Next Generation iPSC Derived Cellular Immunotherapies for Cancer
Next Generation iPSC Derived Cellular Immunotherapies for Cancer
Hanspeter Waldner,
CRISPR Therapeutics, USA
Development of an Allogeneic T Cell Therapy for Oncology
Development of an Allogeneic T Cell Therapy for Oncology
Sonja Schrepfer,
University of California, San Francisco, USA
Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients
Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients
Theodore Roth,
University of California, San Francisco, USA
Short Talk: Highly Parallel Knock-In Targeting for Genome Engineering of Cellular Immunotherapies
Short Talk: Highly Parallel Knock-In Targeting for Genome Engineering of Cellular Immunotherapies
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
DNA Repair and Genome Editing
*
Cecilia Cotta-Ramusino,
Tessera Therapeutics, USA
James E. Haber,
Brandeis University, USA
Understanding Cas9-Mediated Gene Targeting by Single-Strand Template Repair
Understanding Cas9-Mediated Gene Targeting by Single-Strand Template Repair
Pavel Zrazhevskiy,
Altius Institute for Biomedical Sciences, USA
Short Talk: Single Molecule Imaging of Nuclease-Induced Double Strand Break Repair in Human Cells
Short Talk: Single Molecule Imaging of Nuclease-Induced Double Strand Break Repair in Human Cells
Gaëlle Legube,
Center for Integrative Biology, France
Transcription Coupled DNA Double Strand Break Repair: Dealing with Breaks on Transcribed Loci
Transcription Coupled DNA Double Strand Break Repair: Dealing with Breaks on Transcribed Loci
Coffee Break
Jonathan K. Watts,
University of Massachusetts Medical School, USA
Chemically Modified DNA Donors for Precision Genome Editing
Chemically Modified DNA Donors for Precision Genome Editing
Albert B. Seymour,
Homology Medicines, USA
AAVHSC-Mediated Genome Editing through Homologous Recombination: Applications in Liver-Mediated Diseases
AAVHSC-Mediated Genome Editing through Homologous Recombination: Applications in Liver-Mediated Diseases
Manda Arbab,
Harvard University and Broad Institute, USA
Short Talk: Predictable and Precise Genome Editing Enabled by Systematic Characterization of Editing Outcomes
Short Talk: Predictable and Precise Genome Editing Enabled by Systematic Characterization of Editing Outcomes
08:00—11:15
Using Synthetic Biology to Enhance Safety and Efficacy of Cellular Therapeutics
*
Alex Marson,
University of California, San Francisco, USA
Christine E. Brown,
Beckman Research Institute, City of Hope, USA
Advancing CAR T Cell Therapy for Treatment of Brain Tumors
Advancing CAR T Cell Therapy for Treatment of Brain Tumors
Kole T. Roybal,
University of California, San Francisco, USA
Engineering Next-Generation Immune Cell Therapies for Solid Tumors
Engineering Next-Generation Immune Cell Therapies for Solid Tumors
Coffee Break
Marius Wernig,
Stanford University, USA
How to Make a Neuron
How to Make a Neuron
H. Kay Chung,
The Salk Institute for Biological Studies, USA
Short Talk: A Compact Synthetic Pathway Rewires Cancer Signaling to Therapeutic Effector Release
Short Talk: A Compact Synthetic Pathway Rewires Cancer Signaling to Therapeutic Effector Release
Andrew Ng,
University of California, San Francisco, USA
Short Talk: Modular and Tunable Biological Feedback Control Using a De Novo Protein Switch
Short Talk: Modular and Tunable Biological Feedback Control Using a De Novo Protein Switch
Nika Shakiba,
Massachusetts Institute of Technology, USA
Short Talk: Synthetic Genetic Feedback Control Circuits to Reprogram Cell Fate
Short Talk: Synthetic Genetic Feedback Control Circuits to Reprogram Cell Fate
Noreen Wauford,
Massachusetts Institute of Technology, USA
Short Talk: Development of a Toggle Switch Based on Post-Transcriptional Regulation that Resists Epigenetic Silencing
Short Talk: Development of a Toggle Switch Based on Post-Transcriptional Regulation that Resists Epigenetic Silencing
Louai Labanieh,
Stanford University, USA
Short Talk: Genetically-Encoded Switches for Improving CAR-T Immunotherapy
Short Talk: Genetically-Encoded Switches for Improving CAR-T Immunotherapy
17:00—18:45
New Genome Editing Tools
*
Scot A. Wolfe,
University of Massachusetts Medical School, USA
Erik Sontheimer,
University of Massachusetts Medical School, USA
Editing Genomes with Engineered Guide RNAs and Compact, Accurate Cas9 Homologs
Editing Genomes with Engineered Guide RNAs and Compact, Accurate Cas9 Homologs
Yan Zhang,
University of Michigan, USA
Long-Range Genome Engineering in Human Cells with CRISPR-Cas3
Long-Range Genome Engineering in Human Cells with CRISPR-Cas3
David R. Liu,
Broad Institute, HHMI, and Harvard University, USA
Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks
Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks
Peter J. Chen,
Harvard University, USA
Short Talk: Programmable m6A Modification of RNA with a Cas13-Directed Methyltransferase
Short Talk: Programmable m6A Modification of RNA with a Cas13-Directed Methyltransferase
17:00—18:45
Non-T Immune Cell Therapies
*
Crystal L. Mackall,
Stanford University, USA
Katy Rezvani,
University of Texas MD Anderson Cancer Center, USA
Off-The-Shelf CAR-Engineered Cord Blood-Derived NK Cells for the Treatment of Cancer
Off-The-Shelf CAR-Engineered Cord Blood-Derived NK Cells for the Treatment of Cancer
Jeffrey S. Miller,
University of Minnesota, USA
Novel Strategies to Activate and Target NK Cells as Off-The-Shelf Therapy to Treat Cancer
Novel Strategies to Activate and Target NK Cells as Off-The-Shelf Therapy to Treat Cancer
Leonid S. Metelitsa,
Baylor College of Medicine, USA
NKT Cells as a Platform for Adoptive Cancer Immunotherapy
NKT Cells as a Platform for Adoptive Cancer Immunotherapy
Eric Lagasse,
University of Pittsburgh, USA
Short Talk: The Lymph Node as an Ectopic Transplantation Site for Hepatocytes
Short Talk: The Lymph Node as an Ectopic Transplantation Site for Hepatocytes
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
![]() |
![]() |
We gratefully acknowledge additional support from these exhibitors at this conference:
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |